ReviewInternational immunology2016
Group 3 innate lymphoid cells: regulating host-commensal bacteria interactions in inflammation and cancer.
Review in International immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- The soldiers needed to be awakened: Tumor-infiltrating immune cells.Frontiers in genetics · 2022Pooled it
- Microbiome-targeted nanoplatforms and engineering approaches in breast cancer therapy.Molecular cancer · 2025Review
- Elucidating the roles of the mammary and gut microbiomes in breast cancer development.Frontiers in oncology · 2023Review
- Review
- Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer.Cell · 2021Article
- Ambiguous roles and potential therapeutic strategies of innate lymphoid cells in different types of tumor.Oncology letters · 2020Review
- Memory T cells: strategies for optimizing tumor immunotherapy.Protein & cell · 2020Review
- Orchestration of intestinal homeostasis and tolerance by group 3 innate lymphoid cells.Seminars in immunopathology · 2018Review
- Article
- Article
- Pathogenic Role of IL-17-Producing Immune Cells in Obesity, and Related Inflammatory Diseases.Journal of clinical medicine · 2017Review
- Interleukin-17 Is Required for Control of Chronic Lung Infection Caused by Pseudomonas aeruginosa.Infection and immunity · 2016Article
- Emerging roles for antigen presentation in establishing host-microbiome symbiosis.Immunological reviews · 2016Review
- mTOR Mediates IL-23 Induction of Neutrophil IL-17 and IL-22 Production.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Intestinal bacterium-derived cyp27a1 prevents colon cancer cell apoptosis.American journal of translational research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
A delicate balance exists between the mammalian immune system and normally beneficial commensal bacteria that colonize the gastrointestinal tract, which is necessary to maintain tissue homeostasis. Dysregulation of these interactions between the host and commensal bacteria is causally associated with chronic inflammation and the development of cancer. In contrast, recent reports have highlighted that commensal bacteria also play an essential role in promoting anti-tumor immune responses in several contexts, highlighting a paradox whereby interactions between the host and commensal bacteria can influence both pro- and anti-tumor immunity. Given the critical roles for group 3 innate lymphoid cells (ILC3s) in regulating inflammation, tissue repair and host-microbe interactions in the intestine, here we discuss new evidence that ILC3s may profoundly influence the development, progression and control of tumors. In this review, we provide an overview of recent advances in understanding the impact of commensal bacteria on tumorigenesis, discuss recent findings identifying ILC3s as critical regulators of host-microbe interactions and highlight the emerging role of this immune cell population in cancer and their potential implication as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.